Division of Amgen Inc.
Latest From Micromet Inc.
TCR2 Therapeutics raised a $125m Series B round to take two T-cell receptor (TCR)-based therapies into the clinic for solid tumors. The company's technology platform overcomes HLA-matching issues to make TCR-based treatments available to more patients.
The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.
Amgen is validating targets through the deCODE Genetics investment it made five years and moving drugs into the clinic. It's one of multiple technologies – along with its BiTE and oncolytic virus platforms – that R&D head Sean Harper said is starting to bear fruit for the company.
- Large Molecule
- Therapeutic Areas
- Micromet AG
- North America
- Parent & Subsidiaries
- Amgen Inc.
- Senior Management
Patrick A Baeuerle, PhD, SVP, CSO
Jan Fagerberg, MD, PhD, SVP, CMO
Joseph Lobacki, Chief Commercial Officer
- Contact Info
Phone: (240) 752-1420
9201 Corp. Blvd.
Rockville, MD 20850
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.